Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01DK136788-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
| The Pittsburgh Foundation | OTHER |
Not provided
Not provided
Not provided
Day-to-day self-management by adults with type 2 diabetes, including glucose monitoring, taking medications, and healthy habits, is essential to avoid diabetes complications, yet, despite the rapidly expanding availability of wearable glucose and activity monitors, successful self-management remains challenging for many. This research aims to develop and test an approach to help adults use their personal diabetes information from wearable devices to achieve and sustain health diabetes self-management, which will reduce diabetes complications, and improve health and quality of life for people with type 2 diabetes.
MPowerHub trial protocol feasibility will be assessed by randomizing 80 adults with type 2 diabetes and glycemic levels above clinical goals to MPowerHub (MPowerHub platform + continuous glucose monitoring & activity monitoring), continuous glucose monitor alone, or activity monitor alone for four months. Mixed quantitative and qualitative assessments will examine recruitment, engagement, and retention metrics and feedback. Finally, changes in self-management behaviors (measured using semi-structured interview) and clinic glycemic levels (obtained from participants' electronic health record or finger-stick by study research staff) from pre- to post-monitoring will be compared between arms.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MPowerHub | Experimental | Participants will:
|
|
| Continuous Glucose Monitor (CGM) Only | Active Comparator | Participants will:
|
|
| Activity Monitor Only | Active Comparator | Participants will:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MPowerHub | Device | The MPowerHub app allows participants to visualize combined trends from a continuous glucose monitor (CGM) and activity monitor as well as daily self-reports in a display that the participant can customize to overlay the behavioral data they would like to compare to intraday and daily glucose data. Summary data will be displayed over time to allow users to identify potential associations between activity, sleep, stress, diet, and medication adherence and time-in-range and blood glucose variability. Participants receive daily prompts to complete five brief questions about daily health behaviors and two weekly goals/action plans and reflections based on motivational interviewing principles. |
| Measure | Description | Time Frame |
|---|---|---|
| Percent of eligible individuals who enroll in the study | Percent of individuals contacted and found eligible who enroll in the study. The goal benchmark is >/=60%. | Pre-baseline |
| Percent of days wearable device data is collected | Percent of days adequate wearable device data is collected during the 4-month intervention. The goal benchmark is >/=75%. | From 0 to 4 months |
| Percent participants retained in study to the 4-month outcome assessment | Percent of participants retained in the study through the 4-month outcome assessment. The goal benchmark is >/=85%. | From 0 to 4 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percent of individuals contacted who enroll in the study | Percent among all individuals approached/contacted who enroll in the study. The goal benchmark is >/=20%. | Pre-baseline |
| Percent of days self-report data is collected |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ann-Marie Rosland, MD, MS | University of Pittsburgh | Principal Investigator |
| Carissa Low, PhD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | United States |
Data derived from the trial will be eligible to be shared. Data sets will include only "limited access data" (i.e., no records with personal identifiers). Data sets will be de-identified prior to distribution, and wearable sensor data will be aggregated at a level that is determined to preserve individual confidentiality. Data sharing will follow the NIDDK Policy for Data Sharing (https://niddk.nih.gov/research-funding/research-resources/data-management-sharing).
Data underlying publication will be made available on the study publication date. Data not used in publications will be prepared for sharing by the completion of the award and will remain available for at least five years.
Data requests must be submitted in writing using a structured data request form. All data requests will be reviewed by the Multiple PIs (MPIs) and subject to the join approval of the MPIs and co-investigators prior to sharing. Requesters will be required to sign a data use agreement prior to receiving access to the data. The requesting institution's IRB or equivalent body must approve the requested use. All data sharing will follow institutional policies and local IRB rules, as well as local, state, and Federal laws and regulations including the HIPAA Privacy Rule.
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D000079102 | Empowerment |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000072936 | Fitness Trackers |
| ID | Term |
|---|---|
| D019719 | Diagnostic Equipment |
| D004864 | Equipment and Supplies |
| D000076251 | Wearable Electronic Devices |
| D055615 | Electrical Equipment and Supplies |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Continuous Glucose Monitor (CGM) | Device | A CGM is a wearable device that collects frequent data on glucose levels. It includes an integrated sensor that is inserted under the skin and is connected to a small transmitter that automatically sends information to a smart device, allowing the user to track changes in glucose levels. |
|
| Activity Monitor | Device | A wearable activity monitor will be used to track activity (e.g., steps) and sleep levels. Data can be viewed on the activity monitor or a smart device. |
|
Percent of days self-report data is collected from participants in MPowerHub study arm. The goal benchmark is >/=75%.
| From 0 to 4 months |
| Percent of weeks participant responds to goal-setting prompts | Percent of weeks participants in MPowerHub study arm respond to goal-setting prompts. The goal benchmark is >/=65%. | From 0 to 4 months |
| Participant satisfaction with intervention | Study specific Likert-scaled survey item will be used to assess overall intervention satisfaction by participants. Response options range from 1=highly unsatisfied to 5=highly satisfied. Satisfaction will be defined as a rating of 4=satisfied or 5=highly satisfied. The goal benchmark is >/=80% satisfaction for the MPowerHub arm. The results for MPowerHub arm will also be compared to the two other arms. | 4 months |
| Change in hemoglobin A1c | Hemoglobin A1c (HbA1c) data will be obtained from participant's electronic health record. The most recent HbA1c value recorded within 0-6 months prior to enrollment will be used for the baseline measure, and the most recent value recorded at 4-6 months post-enrollment will be used for the outcome measure. If no results from routine HbA1c have been recorded during the relevant time period, the outcome HbA1c data will be collected with a National Glycohemoglobin Standardization Program-certified point of care instrument. | Baseline vs 4-6 Months |
| Change in diabetes medication regimen | Prescribed diabetes medications will be obtained from the participant's electronic health record. A change in diabetes medication regimen assessed by calculating the change in diabetes medication class, e.g., adding or subtracting a class or classes. The range could be negative to positive (e.g., -2, -1, 0, +1, +2) depending on if and how many classes changes occurred. | From baseline to 4-6 months |
| Started on insulin | Prescribed insulin during the course of the intervention will be obtained from the participant's electronic health record and documented as yes/no. | From baseline to 4-6 months |
| Change in medication adherence | Medication adherence will be assessed using the self-report Domains of Subjective Extent of Nonadherence (DOSE-Nonadherence) scale, which is comprised of 3 items assessing the extent to which participants missed, skipped, or did not take their medication as prescribed during the past 7 days. Possible scores range from 1=none of the time to 5=every time with a lower score indicating a greater degree of adherence. Items are summed and scores are averaged. The higher the score, the greater the nonadherence. | Baseline vs. 4 Months |
| Change in healthy eating | Healthy eating will be assessed using the "overall health eating" Summary of Diabetes Self-Care Activities (SDSCA) scale. Participants will be asked how many of the last 7 days have they followed a healthy eating plan (0=no days and 7=all the days). The higher the score, the healthier the eating plan. | Baseline vs 4 Months |
| Change in fruit and vegetable intake per day | Change in fruit and vegetable intake will be assessed using the 6-item Behavioral Risk Factor Surveillance System (BRFSS) 2017 Fruit and Vegetable Module. Change in daily frequency of fruit and vegetable intake will be calculated using the BRFSS scoring algorithm. | Baseline vs 4 months |
| Change in physical activity | Change in physical activity will be assessed using the International Activity Questionnaire - Short Form (IPAQ-SF). The IPAQ-SF asks respondents to report their frequency and duration of walking, moderate-intensity activity, and vigorous-intensity activity in minutes or hours per day. Our study will score results within each domain separately. Responses will be converted into metabolic equivalent of task (MET) minutes; the higher the MET minutes, the higher the degree of physical activity. | Baseline vs 4 Months |
| Change in goal setting | Change in goal setting will be assessed using the Patient Assessment of Chronic Illness Care (PACIC) survey. The PACIC includes three questions about thoughts and actions around setting diabetes goals with 5-point Likert scales (almost never to almost always). Scores will be summed from 3 (all almost never) to 15 (all almost always) and averaged with higher scores reflecting better goal setting. | Baseline vs 4 months |
| Change in intrinsic motivation | Change in intrinsic motivation will be assessed using the Treatment Self-Regulation Questionnaire (TSRQ) Concerning Diabetes Scale A. The scale includes 3 questions related to autonomous regulation questions measured through a 7-point Likert scale, where 1 is "not at all true", 4 is "somewhat true", and 7 is "very true". Scores will be summed and divided by the total number of items. The higher the score, the higher the level of autonomous regulation. | Baseline vs 4 months |
| Change in extrinsic motivation | Change in extrinsic motivation will be assessed using the Treatment Self-Regulation Questionnaire (TSRQ) Concerning Diabetes Scale A. The scale includes 5 questions related to controlled regulation questions measured through a 7-point Likert scale, where 1 is "not at all true", 4 is "somewhat true", and 7 is "very true". Scores will be summed and divided by the total number of items. The higher the score, the higher the level of controlled regulation. | Baseline vs 4 months |
| Change in empowerment | Change in empowerment will be assessed using the Diabetes Empowerment Scale-Short Form (DES-SF). Participants will be asked to respond to 8 questions measured through a 5-point Likert scale (strongly disagree to strongly agree). Scores will be summed and divided by the total number of items. The higher the score indicates a higher level of empowerment. | Baseline vs 4 months |
| Change in diabetes distress - overall | Change in overall diabetes distress will be assessed using the Diabetes Distress Scale - 17 (DDS17), which yields a total diabetes distress score. To score, participant's responses to the appropriate items are summed and divided by the number of items in the scale (possible range 1-6). The higher the score indicates a higher level of distress. | Baseline vs 4 months |
| Change in diabetes distress - emotional burden | Change in emotional burden will be assessed using the Diabetes Distress Scale - 17 (DDS17), which yields a subscale score addressing emotional burden. To score, participant's responses to the appropriate items are summed and divided by the number of items in the emotional burden subscale, possible range 1-6). The higher the score indicates a higher level of distress. | Baseline vs 4 months |
| Change in diabetes distress - regimen distress | Change in regimen distress will be assessed using the Diabetes Distress Scale - 17 (DDS17), which yields a subscale score addressing regimen distress. To score, participant's responses to the appropriate items are summed and divided by the number of items in the regimen distress subscale, possible range 1-6). The higher the score indicates a higher level of distress. | Baseline vs 4 months |
| Participant rating of intervention usability | Intervention usability will be assessed using the System Usability Scale. Participants will be asked to respond to 10 questions measured through a 5-point Likert scale (strongly disagree to strongly agree). To score, values are converted to 0 to 4 by subtracting one from odd item scale positions and subtracting the scale position from five for even-numbered items. Converted responses are summed and the total is multiplied by 2.5; the converted range of possible values is from 0 to 100 (with 100 being the most positive response). | 4 months |
| Participant perceptions of the benefit of continuous glucose monitoring systems | Perceptions about the benefits of continuous glucose monitoring (CGM) systems will be assessed using the Perceived Benefits of CGM (BenCGM) scale. Participants in the MPowerHub and CGM study arms will be asked 8 questions measured with a 5-point Likert scale (strongly disagree to strongly agree). Item scores are summed and range from 8 (all strongly disagree) to 40 (all strongly agree). | 4 months |
| Participant perceptions of the barriers of continuous glucose monitoring systems | Perceptions about the barriers of continuous glucose monitoring (CGM) systems will be assessed using the Perceived Barriers of CGM (BurCGM) scale. Participants in the MPowerHub and CGM study arms will be asked 8 questions measured with a 5-point Likert scale (strongly disagree to strongly agree). Item scores are summed and range from 8 (all strongly disagree) to 40 (all strongly agree). | 4 months |
| D004700 | Endocrine System Diseases |
| D012919 | Social Behavior |
| D001519 | Behavior |